Novo Nordisk Pharmatech showing latest cGMP quats at CPhI Frankfurt


Novo Nordisk Pharmatech showing latest cGMP quats at CPhI Frankfurt


NovoNordics 150x58

Press Release | Novo Nordisk Pharmatech A/S

SEPTEMBER 20, 2017

Koege , Denmark: – Novo Nordisk Pharmatech A/S, the leading worldwide supplier of high-quality ingredients for the biopharmaceutical, pharmaceutical and personal care industries, will be exhibiting its latest cGMP high purity ‘quats’ line of quaternary ammonium compounds at CPhI Worldwide in Frankfurt.

The Danish-based specialist will be exhibiting at stand 80M43 at the Messe Frankfurt exhibition center, showcasing the company’s recently developed quats, manufactured in accordance with cGMP Guide ICH Q7 for Active Pharmaceutical Ingredients, the highest available standard. The company is already accepting booking for personal meetings at CPhI Frankfurt.

Regulatory and production assistance

Novo Nordisk Pharmatech’s innovative synthesis process makes the CMO a leading supplier of Benzalkonium Chloride, Cetrimide and CTAB, with high purity levels that makes them particularly suited for pharmaceutical applications, such as vaccine production. They are analyzed according to relevant multicompendial pharmacopoeias such as Ph.Eur., USP/NF, JP and BP. Novo Nordisk Pharmatech is also one of the world’s leading suppliers of recombinant insulin in cell culture media, powering biopharma blockbuster drugs worldwide.

“We are ready to reach out to any pharma or biotech companies looking for absolute quality, purity and traceability from their Quats supplier,” said Novo Nordisk Product Manager, Chantale Julien.

“Our pharma-grade Quats are manufactured to the highest cGMP regulations and delivered to specific standards, so we’ll be able to show that we’re able to help our partners with their potential regulatory, quality and production issues,” said Ms. Julien.

Innovative synthesis

“Our Quats are focused on vaccine manufacture and healthcare products, acting either as preservatives or active ingredients in many ophthalmic, nasal, oral and topical drugs and in a variety of solutions, ointments and creams,” Ms. Julien explained.

“Whether it’s Benzalkonium Chloride, CTAB, Cetrimide or Strong Cetrimide Solution for ophthalmic, nasal sprays, topicals, oral products or medical devices, we know that our partners businesses depend upon absolute confidence in supply quality – so we’ve built our business to deliver the absolute quality needed,” she added.

“Biosimilar manufacturers need to keep a strong focus on the manufacturing process of originator drugs. Using Novo Nordisk Pharmatech compounds reduces the risk of deviations in the process,” said Julien, who will be part of the Novo Nordisk stand team, on hand to answer technical questions.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, and now part of the Novo Nordisk pharmaceutical group since its acquisition in 1986. On September1, 2015, the company became Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.

The company markets its diabetic care, hemophilia, growth hormone therapy, obesity, and hormone replacement therapy (HRT) products worldwide, with customers in more than 180 countries.

All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.

For Financial Year 2016, Novo Nordisk Pharmatech reported world sales totaling 669 million Danish kroner (DEK) with more than half of all sales recorded in North America.

About CPhI Worldwide 2017

CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors networking opportunities with potential international pharmaceutical partners and collaborators, as well as latest industry insights.

Now in its 28th year, CPhI 2017 is a three-day event opening October 24 at the Messe Frankfurt exhibition center. Last year’s event in Barcelona attracted some 42,000 delegates and more than 2,500 exhibitor companies from 155 countries worldwide.

CPhI Worldwide is held alongside four other zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment, InnoPack pharmaceutical packaging and a new addition, the FDF show for Finish, Dosage and Formulations, bringing together every aspect of the finished dosage supply chain.

The CPhI Pharma Awards, presented on the first evening of the conference, honor innovative companies and leaders.

The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: www.cphi.com/europe

Media Contact

Vanessa León, Marketing Manager, Novo Nordisk Pharmatech A/S
Tel:+45 404 262 84
Email: vnlt@novonordiskpharmatech.com

Resources

Click on Novo Nordisk Pharmatech showing cGMP grade quats at CPhI Frankfurt for more information.
Click on Novo Nordisk Pharmatech to contact the company directly.
click on CPhI Booking to book a meeting with Novo Nordisk.


Supplier Information
Supplier: Novo Nordisk Pharmatech A/S
Address: Koebenhavnsvej 216, 4600 Koege, Denmark
Tel: +45 566 71000
Fax: + 33 38 331 2483
Website: http://novonordiskpharmatech.com/


Comments are closed.